Ebara Shin, Katayama Norihisa, Tanimoto Ryuta, Edamura Kohei, Nose Hiroyuki, Manabe Daisuke, Kobayashi Tomoko, Kobayashi Yasuyuki, Kobuke Makoto, Takemoto Mitsuhiro, Saika Takashi, Nasu Yasutomo, Kanazawa Susumu, Kumon Hiromi
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Acta Med Okayama. 2008 Feb;62(1):9-13.
From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treated using iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatments efficacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classified as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml). The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7%) complained of difficulty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the first month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and effective for localized prostate cancer within short-term follow up.
2004年1月至2007年3月，308例临床局限性前列腺癌患者在冈山大学医学、牙医学和药学研究生院接受了碘-125（¹²⁵I）粒子植入（永久性近距离放射治疗）。我们评估了300例在近距离放射治疗后随访超过1个月的前列腺癌患者的治疗效果和发病率。根据美国国立综合癌症网络（NCCN）指南，经直肠超声成像显示前列腺体积小于40 ml的患者被归类为低风险或中风险。患者年龄中位数为67岁（范围50至79岁），活检前前列腺特异性抗原（PSA）值中位数为6.95 ng/ml（范围1.13至24.7 ng/ml），前列腺体积中位数为24.33 ml（范围9.3至41.76 ml）。中位随访时间为18个月（范围1至36个月），近距离放射治疗后几乎所有患者的PSA水平均下降。尽管300例患者中有194例（64.7%）抱怨排尿困难、尿频/尿急、排尿疼痛和/或尿失禁，所有这些症状可能与近距离放射治疗后第一个月的放射性前列腺炎有关，但这些症状逐渐改善。¹²⁵I粒子植入近距离放射治疗在短期随访中对局限性前列腺癌是安全有效的。
